Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biosimilar Pegfilgrastim vs Filgrastim Post-ASCT
NCT06116734Phase 3Unknown
- Start
- Nov 2023
- Primary completion
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of pegfilgrastim in febrile neutropenia (FN). Status: unknown.
02
Drugs
pegfilgrastim
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on NCT06116734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06116734.